Medical Isotope Potential
A 14 MeV source can reach production routes for certain medical and research isotopes — a potential service, stated cautiously and without economics.
A potential, framed honestly
The medical-isotope supply chain depends heavily on a small number of aging fission reactors, and shortages of key diagnostic and therapeutic isotopes have been a recurring problem. A fusion neutron source offers alternative production routes, particularly for isotopes best reached by fast or threshold reactions that fission spectra do not favor.
Kronos states this as a potential, not a committed product. Realizing medical-isotope production requires target chemistry, hot-cell processing, radiochemical purification, and stringent regulatory qualification for medical use — a substantial program beyond simply having neutrons. The physics capability is real; the pathway to certified medical product is long.
Why a fusion source is interesting here
- Threshold (n,2n)/(n,p) routes can yield high-specific-activity products
- Carrier-free production for some isotopes via specific reactions
- Diversifies supply away from a fragile fission-reactor base
- Complements activation and neutron-services offerings
Honest limits
No medical isotope is claimed as a deliverable of Hyperion today. The machine is a design-and-simulation study, and any medical-isotope service would follow its own qualification and licensing path well after FOAK. This page describes physical potential only and makes no commercial claim of any kind.
This page describes a design-and-simulation study, not a built machine. Construction begins Q2 2027; first-of-a-kind (FOAK) first tritium is targeted near 2030. No net-gain claim is made before FOAK.